Game On

Target Audience

The design of this activity addresses the needs of clinical immunologists, allergists, dermatologists, gastroenterologists and hematology/oncology clinicians and other healthcare professionals who manage patients with nonadvanced systemic mastocytosis (SM).

Program Overview

Nonadvanced SM is a rare, often misdiagnosed condition associated with high symptom burden and significant quality-of-life impact. This interactive program features a didactic overview of pathophysiology, diagnosis, and evolving treatment strategies of nonadvanced SM, followed by a fun and engaging Medical Jeopardy™-style game to reinforce key concepts.

Learning Objectives

After completing this activity, the participant should be better able to:

• Explain the underlying causes and effects of nonadvanced SM, with an emphasis on its clinical manifestations and the pathophysiological basis for targeted therapies

• Differentiate SM, including indolent forms, by recognizing key symptoms and appropriately utilizing laboratory and genetic testing

• Summarize clinical trial findings for emerging and established therapies, including FDA-approved treatments

• Tailor treatment plans for nonadvanced SM by incorporating clinical evidence, safety considerations, patient-reported outcomes, shared decision-making, and patient education

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must take the pretest, view the content, pass the posttest with a 70% or higher, and complete the evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

• Matthew P. Giannetti, MD - Consulting, medical safety board: Cogent Biosciences, Inmagene; Research funding: Blueprint Medicines Corporation
• Anne L. Maitland, MD, PhD - Consulting Fees: Blueprint Medicines Corporation; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Blueprint Medicines Corporation
• Tsewang Tashi, MD - Consulting Fees: Blueprint Medicines Corporation, Cogent Biosciences, PharmaEssentia

The Integritas Communications planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.